Five out of 37 (14%) PUP and 4 out of 23 (17%) MTP patients treated with KOGENATE Bayer developed inhibitors:
Cinco de los 37 pacientes PUPs (14%) y 4 de los 23 MTPs (17%) tratados con KOGENATE Bayer desarrollaron inhibidores: